You are here

  • Home
  • Online First
  • Tyrosine kinase inhibitor use in idiopathic pulmonary fibrosis

Article Text

Article menu

other Versions

Download PDFPDF
Miscellaneous
Journal club
Tyrosine kinase inhibitor use in idiopathic pulmonary fibrosis
  1. Alan G Dawson
  1. Correspondence to Dr Alan G Dawson, Academic Foundation Year Two, Aberdeen Royal Infirmary, Department of Cardiothoracic Surgery, Foresterhill, Aberdeen AB25 2ZN, Scotland, UK; alan.g.dawson.04{at}aberdeen.ac.uk

https://doi.org/10.1136/thoraxjnl-2011-201439

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    This randomised, multicentre, double-blind, placebo-controlled trial evaluated the efficacy and safety of four different doses of BIBF 1120, a tyrosine kinase inhibitor, in order to investigate its effect on progression of idiopathic pulmonary fibrosis (IPF).

    The annual rate of decline in forced vital capacity (FVC), the primary end-point of this study, in the highest dose subgroup compared …

    View Full Text

    Footnotes

    • Provenance and peer review Not commissioned; internally peer reviewed.